A pilot trial evaluating Meta050, a proprietary combination of reduced iso-alpha acids, rosemary extract and oleanolic acid in patients with arthritis and fibromyalgia

Phytotherapy Research

Volumn 19, Issue 10, 2005, Pages 864-869

  Lukaczer, Daniel ^a,b,c   Darland, Gary ^b   Tripp, Matthew ^b   Liska, DeAnn ^b   Lerman, Robert H ^a,b   Schiltz, Barbara ^a,b   Bland, Jeffrey S ^b  

^a Clinical Research at the Functional Medicine Research Center   (United States)

^b Metagenics Inc   (United States)

^c Functional Medicine Research Center   (United States)

Author keywords

Arthritis pain; Oleanolic acid; Osteoarthritis; Reduced iso alpha acids; Rheumatoid arthritis; Rosmarinus officinalis extract

Indexed keywords

C REACTIVE PROTEIN; HUMULUS LUPULUS EXTRACT; META 050; OLEA EUROPAEA EXTRACT; PLANT MEDICINAL PRODUCT; ROSMARINUS OFFICINALIS EXTRACT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTHRITIS; ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; FEMALE; FIBROMYALGIA; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PAIN ASSESSMENT; QUESTIONNAIRE; RANK SUM TEST; RHEUMATOID ARTHRITIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; VISUAL ANALOG SCALE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FIBROMYALGIA; HUMANS; HUMULUS; MALE; MIDDLE AGED; OLEA; OLEANOLIC ACID; OSTEOARTHRITIS; PAIN MEASUREMENT; PHYTOTHERAPY; PILOT PROJECTS; PLANT EXTRACTS; QUESTIONNAIRES; ROSMARINUS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

HUMULUS LUPULUS; OLEA EUROPAEA; ROSMARINUS OFFICINALIS;

EID: 27944489629     PISSN: 0951418X     EISSN: None     Source Type: Journal    
DOI: 10.1002/ptr.1709     Document Type: Article

References (33)

1. Al-Sereiti MR, Abu-Amer KM, Sen P. 1999. Pharmacology of rosemary (Rosmarinus officinalis Linn.) and its therapeutic potentials. Indian J Exp Biol 37: 124-130.
2. Altman R, Alarcon G, Appelrouth D et al. 1991. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 34: 505-514.
3. Altman R, Alarcon G, Appelrouth D et al. 1990. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 33: 1601-1610.
4. Altman R, Asch E, Bloch D et al. 1986. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 29: 1039-1049.
5. Arnett FC, Edworthy SM, Bloch DA et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324.
6. Astudillo L, Rodriguez JA, Schmeda-Hirschmann G. 2002. Gastroprotective activity of oleanolic acid derivatives on experimentally induced gastric lesions in rats and mice. J Pharm Pharmacol 54: 583-588.
7. Averbuch M, Katzper M. 2004. Assessment of visual analog versus categorical scale for measurement of osteoarthritis pain. J Clin Pharmacol 44: 368-372.
8. Burckhardt CS, Clark SR, Bennett RM. 1991. The fibromyalgia impact questionnaire: development and validation. J Rhematol 18: 728-733.
9. Chikanza IC, Fernandes L. 2000. Novel strategies for the treatment of osteoarthritis. Exp Opin Invest Drugs 9: 1499-1510.
10. Choy EHS, Panayi GS. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344: 907-916.
11. Cohen M, Wolfe R, Mai T, Lewis D. 2003. A randomized, double-blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. J Rheumatol 30: 523-528.
12. del Bano MJ, Lorente J, Castillo J et al. 2003. Phenolic diterpenes, flavones, and rosmarinic acid distribution during the development of leaves, flowers, stems, and roots of Rosmarinus officinalis. Antioxidant activity. J Agric Food Chem 51: 4247-4253.
13. FitzGerald GA. 2003. Cox-2 and beyond: approaches to prostaglandin inhibition in human disease. Nature Rev 2: 879-890.
14. Haavardsholm EA, Kvien TK, Uhlig T, Smedstad LM, Guillemin F. 2000. A comparison of agreement and sensitivity to change between AIMS2 and a short form of AIMS2 (AIMS2-SF) in more than 1000 rheumatoid arthritis patients. J Rheumatol 27: 2810-2816.
15. Kivitz A, Moskowitz RW, Woods E et al. 2001. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Intern Med Res 29: 467-479.
16. Kosinski M, Keller SD, Ware JE Jr, Hatoum HT, Kong SX. 1999. The SF-36 health survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: relative validity of scales in relation to clinical measures of arthritis severity. Med Care 37(Suppl 5): MS23-MS39.
17. Lerman R, Babish J, Lukaczer D et al. 2003. Ex vivo clinical study of the anti-inflammatory activity of a proprietary synergistic blend of hops extract, rosemary, and oleanolic acid. [abstract]. FASEB Abstract 83590.
18. Liu J. 1995. Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 49: 57-68.
19. Lo AH, Liang YC, Lin-Shiau SY, Ho CT, Lin JK. 2002. Carnosol, an antioxidant in rosemary, suppresses inducible nitric oxide synthase through down-regulating nuclear factor-kappaB in mouse macrophages. Carcinogenesis 23: 983-991.
20. Maes M, Libbrecht I, Van Hunsel F et al. 1999. The immune-inflammatory pathophysiology of fibromyalgia: increased serum soluble gp130, the common signal transducer protein of various neurotrophic cytokines. Psychoneuroendocrinology 24: 371-383.
21. McCoy JM, Wicks JR, Audoly LP. 2002. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest 110: 651-658.
22. Moss M, Cook J, Wesnes K, Duckett P. 2003. Aromas of rosemary and lavender essential oils differentially affect cognition and mood in healthy adults. Int J Neurosci 113: 15-38.
23. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). 1998. Arthritis prevalence rising as baby boomers grow older osteoarthritis second only to chronic heart disease in worksite disability. Press Release: May 5, 1998. Available at: http://www.niams.nih.gov/ne/press/ l998/ 05_05.htm. Accessed May 18, 2004.
24. Neumann L, Berzak A, Buskila D. 2000. Measuring health status in Israeli patients with fibromyalgia syndrome and wide-spread pain and healthy individuals: utility of the short form 36-item health survey (SF-36). Semin Arthritis Rheum 29: 400-408.
25. Pelletier JP, Martel-Pelletier J, Abramson SB. 2001. Osteoarthritis, an inflammatory disease. Arthritis Rheum 44: 1237-1247.
26. Rao JK, Kroenke K, Mihaliak KA, Grambow SC, Weinberger M. 2003. Rheumatology patients' use of complementary therapies: results from a one-year longitudinal study. Arthritis Rheum 49: 619-625.
27. Salvador RL. 1994. Hops. Can Pharm J 127: 203-204, 207.
28. Spector TD, Hart DJ, Nandra D et al. 1997. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 40: 723-727.
29. Tripp M, Darland G, Lerman RH et al. 2003. Development of Meta050, a natural anti-inflammatory targeting inhibition of cyclooxygenase gene induction instead of direct cyclooxygenase enzyme inhibition, resulting in an anti-inflammatory with low-predicted GI toxicity. [abstract]. FASEB Abstract 83597.
30. van der Kraan PM, van den Berg WB. 2000. Anabolic and destructive mediators in osteoarthritis. Curr Opin Clin Nutr Metab Care 3: 205-211.
31. Walker-Bone K. 2003. 'Natural remedies' in the treatment of osteoarthritis. Drugs Aging 20: 517-526.
32. Wolfe F, Smythe H, Yunus M et al. 1990. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33: 160-172.
33. Yamamoto K, Wang J, Yamamoto S, Tobe H. 2000. Suppression of cyclooxygenase-2 gene transcription by humulon of beer hop extract studied with reference to glucocorticoid. FEBS Lett 465: 103-106.